WuXi Biologics (Cayman) Inc. (WXIBF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WuXi Biologics (Cayman) Inc. (WXIBF) trades at $4.63 with AI Score 49/100 (Grade C). WuXi Biologics (Cayman) Inc. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for biologics. Market cap: $19.18B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for WXIBF: WXIBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WXIBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
WXIBF: the 1 perspectives are evenly split.
How is this calculated? →WuXi Biologics (Cayman) Inc. (WXIBF) Healthcare & Pipeline Overview
WuXi Biologics is a leading global CDMO providing comprehensive services for biologics, from discovery to manufacturing, serving clients in China, North America, and Europe. With a strong focus on innovation and strategic partnerships, the company plays a crucial role in advancing biopharmaceutical development worldwide, reflected in its P/E ratio of 22.9.
What Is the Investment Thesis for WXIBF?
WuXi Biologics presents a compelling investment case driven by the increasing demand for biologics and the outsourcing of biopharmaceutical development and manufacturing. The company's comprehensive service offerings, global presence, and strategic partnerships position it well to capitalize on this trend. With a profit margin of 20.9% and a gross margin of 42.7%, WuXi Biologics demonstrates strong financial performance. The company's beta of 0.50 suggests lower volatility compared to the overall market. Key growth catalysts include expansion into new therapeutic areas and increased adoption of its integrated services. However, investors should be aware of potential risks such as regulatory changes and competition within the CDMO space.
Based on FMP financials and quantitative analysis
WXIBF Key Highlights
- Market capitalization of $19.18B, reflecting its significant presence in the biologics CDMO market.
- P/E ratio of 22.9, indicating investor expectations for future growth.
- Profit margin of 20.9%, showcasing operational efficiency and profitability.
- Gross margin of 42.7%, highlighting the value-added nature of its services.
- Beta of 0.50, suggesting lower volatility compared to the overall market.
Who Are WXIBF's Competitors?
WXIBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $14.60 | +3.18% | $26.16B | 58 |
| ALPMY Astellas Pharma Inc. | $13.63 | +2.48% | $24.42B | 55 |
| BMXXY bioMérieux S.A. | $7.53 | -6.98% | $8.88B | 46 |
| GNMSF Genmab A/S | $273.50 | -0.55% | $16.79B | 55 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WXIBF's Key Strengths?
- Comprehensive service offerings
- Global presence
- Strong reputation
- Strategic partnerships
What Are WXIBF's Weaknesses?
- Reliance on outsourcing trends
- Exposure to regulatory changes
- Competition from other CDMOs
- Potential for intellectual property disputes
What Could Drive WXIBF Stock Higher?
- Expansion into new therapeutic areas, such as cell and gene therapy, driving revenue growth.
- Geographic expansion into key markets like Europe and North America, increasing market reach.
- Increased adoption of integrated end-to-end service offerings, capturing a larger share of client spending.
- Strategic partnerships and collaborations with pharmaceutical and biotechnology companies, expanding service offerings.
- Expansion of vaccine CDMO capabilities, capitalizing on the growing demand for vaccine development and manufacturing.
What Are the Key Risks for WXIBF?
- Economic downturn could reduce demand for biologics development and manufacturing services.
- Changes in government regulations could impact the company's operations and profitability.
- Technological advancements by competitors could erode its competitive advantage.
- Loss of key clients could negatively impact revenue and earnings.
- Competition from other CDMOs could put pressure on pricing and margins.
What Are the Growth Opportunities for WXIBF?
- Expansion into New Therapeutic Areas: WuXi Biologics can drive growth by expanding its service offerings into emerging therapeutic areas such as cell and gene therapy. The cell and gene therapy market is projected to reach $36.9 billion by 2025, presenting a significant opportunity for WuXi Biologics to leverage its expertise and infrastructure to capture market share. This expansion can be achieved through strategic partnerships, acquisitions, and internal investments in research and development. Timeline: Ongoing.
- Geographic Expansion: WuXi Biologics can further expand its global footprint by establishing new facilities and partnerships in key markets such as Europe and North America. This geographic diversification will enable the company to better serve its global client base and capitalize on regional growth opportunities. The North American CDMO market is expected to grow at a CAGR of 10% over the next five years, offering substantial growth potential. Timeline: Ongoing.
- Increased Adoption of Integrated Services: WuXi Biologics can drive revenue growth by promoting the adoption of its integrated end-to-end service offerings. By providing a comprehensive suite of services from discovery to manufacturing, the company can streamline the drug development process for its clients and capture a larger share of their outsourcing spend. This strategy requires effective marketing and sales efforts to highlight the benefits of its integrated platform. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: WuXi Biologics can continue to forge strategic partnerships and collaborations with pharmaceutical and biotechnology companies to expand its service offerings and market reach. These partnerships can provide access to new technologies, therapeutic areas, and geographic markets. The company's existing partnerships with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc demonstrate the effectiveness of this strategy. Timeline: Ongoing.
- Vaccine CDMO Expansion: WuXi Biologics can capitalize on the growing demand for vaccine development and manufacturing services by expanding its vaccine CDMO capabilities. The global vaccine market is projected to reach $100 billion by 2025, driven by factors such as the COVID-19 pandemic and increasing awareness of the importance of vaccination. WuXi Biologics can leverage its expertise in biologics manufacturing to capture a significant share of this market. Timeline: Ongoing.
What Opportunities Does WXIBF Have?
- Expansion into new therapeutic areas
- Geographic expansion
- Increased adoption of integrated services
- Growth in the vaccine CDMO market
What Threats Does WXIBF Face?
- Economic downturn
- Changes in government regulations
- Technological advancements by competitors
- Loss of key clients
What Are WXIBF's Competitive Advantages?
- Integrated platform: Provides a comprehensive suite of services, creating a barrier to entry for smaller, specialized CDMOs.
- Global presence: Serves clients in China, North America, and Europe, offering a competitive advantage over regional players.
- Strong reputation: Established track record of quality and reliability, building trust with clients.
- Strategic partnerships: Collaborations with leading pharmaceutical and biotechnology companies, enhancing its capabilities and market reach.
What Does WXIBF Do?
WuXi Biologics (Cayman) Inc., established in 2014 and headquartered in Wuxi, China, is a prominent contract development and manufacturing organization (CDMO) specializing in biologics. The company offers end-to-end solutions encompassing biologics discovery, development, and manufacturing services to clients across the People's Republic of China, North America, Europe, and other international markets. Its comprehensive service portfolio includes consultation in biopharmaceutical technology, international sales contracting, testing technology development, sales and marketing support, and biologics clinical and manufacturing services. WuXi Biologics also engages in the production and sale of medical products, vaccine CDMO services, and material supplier activities. The company has cultivated strategic partnerships with firms such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc, enhancing its capabilities and market reach. With a workforce of 12,575 employees, WuXi Biologics leverages its expertise and infrastructure to support the development and commercialization of innovative biopharmaceuticals, playing a vital role in the global healthcare industry.
What Products and Services Does WXIBF Offer?
- Provides end-to-end solutions for biologics discovery.
- Offers biologics development services.
- Manufactures biologics for pharmaceutical companies.
- Provides consultation services in biopharmaceutical technology.
- Engages in international sales contracting services.
- Develops and tests testing technologies.
- Offers sales and marketing services for biologics.
- Provides biologics clinical and manufacturing services.
How Does WXIBF Make Money?
- Fee-for-service model: Charges clients for specific services rendered throughout the drug development and manufacturing process.
- Integrated platform: Offers a comprehensive suite of services, capturing a larger share of client spending.
- Strategic partnerships: Collaborates with other companies to expand service offerings and market reach.
What Industry Does WXIBF Operate In?
WuXi Biologics operates within the rapidly expanding biotechnology industry, driven by increasing demand for novel biopharmaceuticals and the growing trend of outsourcing drug development and manufacturing. The global CDMO market is expected to continue its growth trajectory, fueled by factors such as rising healthcare expenditures, increasing prevalence of chronic diseases, and the complexity of biologics development. WuXi Biologics competes with other CDMOs, including ALPMF (Alphamab Oncology), ALPMY (Alphamab Oncology), BMXXY (BeiGene Ltd), GNMSF (Genmab A/S), and IVBXF (Invex Therapeutics Ltd), each vying for market share in this dynamic landscape.
Who Are WXIBF's Key Customers?
- Pharmaceutical companies
- Biotechnology companies
- Academic institutions
- Research organizations
How WuXi Biologics (Cayman) Inc. Is Valued
WuXi Biologics (Cayman) Inc. carries a market capitalization of $19.18B, placing it in the large-cap category. Relative to its peer group, WXIBF's quantitative score of 49/100 is roughly in line with the peer average of 56/100.
ROE 11%Key Financial Metrics
Return on equity for WuXi Biologics (Cayman) Inc. stands at 10.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.7%, showing how much profit it generates from its asset base. WXIBF trades at a trailing price-to-earnings ratio of 22.88, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 9/9Financial Health
WuXi Biologics (Cayman) Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.35 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project WuXi Biologics (Cayman) Inc. revenue of about $26.00B for fiscal 2026, with EPS near $1.35. The estimate reflects 22 contributing analysts.
WXIBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive service offerings
- Global presence
- Strong reputation
- Strategic partnerships
Bear Case
- Reliance on outsourcing trends
- Exposure to regulatory changes
- Competition from other CDMOs
- Potential for intellectual property disputes
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
WXIBF Latest News
-
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
Yahoo! Finance: WXIBF News · Jun 18, 2026
-
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
Yahoo! Finance: WXIBF News · Jun 8, 2026
-
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Yahoo! Finance: WXIBF News · Jun 5, 2026
-
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
Yahoo! Finance: WXIBF News · Jun 3, 2026
WXIBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WXIBF.
Price Targets
Wall Street price target analysis for WXIBF.
WXIBF MoonshotScore
What does this score mean?
The MoonshotScore rates WXIBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
Leadership: Zhisheng Chen
CEO
Zhisheng Chen is the CEO of WuXi Biologics, leading a workforce of 12,575 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on manufacturing and operations. He has held various leadership positions in multinational pharmaceutical companies, contributing to the development and commercialization of numerous biologics. His expertise spans process development, scale-up, and GMP manufacturing. He is known for his strategic vision and operational excellence.
Track Record: Under Zhisheng Chen's leadership, WuXi Biologics has experienced significant growth and expansion, solidifying its position as a leading global CDMO. He has overseen the establishment of new facilities, the expansion of service offerings, and the forging of strategic partnerships. Key milestones include the successful commercialization of multiple biologics and the expansion into new therapeutic areas. His focus on innovation and operational efficiency has driven the company's success.
WXIBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that WuXi Biologics (WXIBF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information availability
- Lower liquidity
- Potential for price volatility
- Higher risk of fraud or manipulation
- Less regulatory oversight
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established partnerships with reputable companies
- Positive media coverage and industry recognition
- Experienced management team
- Clear business model and value proposition
- Consistent revenue generation
Common Questions About WXIBF (Healthcare)
What does WuXi Biologics (Cayman) Inc. do?
WuXi Biologics (Cayman) Inc. is a leading global contract development and manufacturing organization (CDMO) that provides end-to-end solutions for biologics. The company supports pharmaceutical and biotechnology companies in the discovery, development, and manufacturing of biopharmaceuticals. Its services encompass a wide range of activities, including cell line development, process development, formulation, clinical and commercial manufacturing, and regulatory support. By offering a comprehensive suite of services, WuXi Biologics helps its clients accelerate drug development timelines and reduce costs, ultimately contributing to the advancement of healthcare.
What are the main risks for WXIBF?
WuXi Biologics (WXIBF) faces several risks inherent to the biotechnology and CDMO industries. These include economic downturns that could reduce demand for its services, changes in government regulations that could impact its operations, and technological advancements by competitors that could erode its competitive advantage. Additionally, the company is exposed to the risk of losing key clients, which could negatively impact revenue and earnings. Competition from other CDMOs could also put pressure on pricing and margins. Investors should carefully consider these risks before investing in WXIBF.
What are the key factors to evaluate for WXIBF?
WuXi Biologics (Cayman) Inc. (WXIBF) holds an AI score of 49/100 (low). P/E: 22.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does WXIBF data refresh on this page?
WXIBF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven WXIBF's recent stock price performance?
WuXi Biologics (Cayman) Inc. (WXIBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WXIBF overvalued or undervalued right now?
WuXi Biologics (Cayman) Inc. (WXIBF) trades at 22.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying WXIBF?
Before investing in WuXi Biologics (Cayman) Inc. (WXIBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding WXIBF to a portfolio?
Key strength of WuXi Biologics (Cayman) Inc. (WXIBF): Comprehensive service offerings. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data and market projections are based on available information and industry reports.
- Analyst consensus is pending AI analysis.
- OTC market data may be limited or inconsistent.